hrp0086p2-p662 | Growth P2 | ESPE2016

High Efficacy Growth Hormone Therapy in Patient with Homozygous Mutation in Growth Hormone Gene (GH-1) During 3 Years

Anna Gavrilova , Elena Nagaeva , Tatyana Shiryaeva

Background: Mutations in GH-1 gene is a rare cause of isolated growth hormone deficiency. Main features of this condition include markedly reduced secretion of GH combined with low concentrations of IGF-I leading to short stature.Objective and hypotheses: 1.56 years old girl was admitted to our hospital because of short stature. She was born at term from closely related healthy parents. Her birth length and weight were 48 cm (SDS: −1.07) a...

hrp0084p3-977 | GH & IGF | ESPE2015

Congenital Hypopituitarism and Severe Developmental Delay Associated with Homozygous POU1F1 Mutation

Melikian Maria , Tiulpakov Anatoly , Gavrilova Anna

Background: Mutations in POU1F1 is a rare cause of combined pituitary hormone deficiency, which commonly includes GH, TSH and prolactin deficiencies and characterised by hypoplastic anterior pituitary.Objective and hypotheses: To present a case of severe short stature and developmental delay 1.5 years old girl, who was admitted to our hospital because of short stature.Method: Hypopituitarism panel’ genes were sequence...

hrp0089p2-p236 | GH & IGFs P2 | ESPE2018

Artificial Neural Networks for Prediction Final Height in Children with growth Hormone Deficiency

Gavrilova Anna , Nagaeva Elena , Rebrova Olga , Shiryaeva Tatiana , Peterkova Valentina

Background: Mathematical models predicting final height (FH) and its standard deviation score (SDS) in children with growth hormone deficiency is an important tool for clinicians to manage treatment process. Previously developed models do not have enough accuracy or are not good enough for practical use.Objective and hypotheses: We used four binary and seven continuous predictors available at the time of diagnosis and start of therapy and developed multi...

hrp0086p2-p647 | Growth P2 | ESPE2016

Final Adult Height (FAH) in Patients with PROR-1 Gene Mutations during GH Long-Term Therapy

Anna Gavrilova , Elena Nagaeva , Tatiana Shiryaeva , Valentina Petekova , Ivan Dedov

Background: PROP-1 gene mutations are responsible for most of the cases of multiple pituitary hormone deficiencies (MPHD).Objective and hypotheses: We performed to evaluate the final adult height (FAH) in a group of patients with a PROP-1 gene mutations. Twenty-five patients (11 males) with a PROP-1 gene mutation, not treated before, were recruited. All the patients had been treated with a fixed rhGH dose (0.033 mg/kg per day) for 10.5 years (7.0–11...

hrp0092p2-109 | Fat, Metabolism and Obesity | ESPE2019

Metabolic Syndrome in Children and Adolescents who Survived After Childhood Cancer

Zhukovskaya Elena , Gavrilova Anna , Nasedkina Tatiana , Chechelnitskaya Serafima , Lisitsa Tatiana , Karelin Alexander , Kasatkin Vladimir , Rumyantsev Alexander

Background/Objectives: During treatment of children and adolescents with cancer, an imbalance of carbohydrate and mineral metabolism may occur, leading to clinical manifestations of the components of the metabolic syndrome. The aim of the work was to study the frequency and severity of various clinical signs associated with metabolic syndrome in a cohort of patients from the Russian Field Clinical Rehabilitation Center.Design/Met...

hrp0084p2-547 | Puberty | ESPE2015

The Impact of Growth Hormone (GH) Therapy Combined with Estrogens on Blood Pressure (BP), Cardiac Left Ventricular (LV) Dimensions and Lipid Metabolism in Pubertal Girls with Turner’s Syndrome (TS)

Nagaeva Elena , Shiryaeva Tatiana , Volevodz Natalia , Chikulaeva Olga , Pankratova Maria , Gavrilova Anna , Peterkova Valentina

Background: The risk of hypertension is estimated to occur in 7–17% of children and adolescents with TS. Even girls with TS who are normotensive have been shown an abnormal circadian BP rhythm, increasing the risk of end-organ hypertensive damage.Objective and hypotheses: We performed this study to assess the effects of GH treatment combined with estrogens for short stature on LV dimensions, systemic BP and lipid metabolism in girls with TS without ...